TRAX (First Tracks Biotherapeutics, Inc. Ordinary Shares) Stock Analysis - Financials

First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is a publicly traded the market company. As of May 21, 2026, TRAX trades at $16.15 with a market cap of $620.74M and a P/E ratio of 0.00. TRAX moved -2.16% today. Year to date, TRAX is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $14.79 to $25.58. Analyst consensus is strong buy with an average price target of $38.50. Rallies surfaces TRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are TRAX's key financials?

TRAX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRAX recently traded at $16.15. Market cap is $620.74M. P/E ratio is 0.00. Revenue is $0.

TRAX Key Metrics

Key financial metrics for TRAX
MetricValue
Price$16.15
Market Cap$620.74M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$25.58
52-Week Low$14.79
Volume84
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest TRAX News

Recent TRAX Insider Trades

  • EcoR1 Capital, LLC bought 4.71M (~$65.00M) on Apr 20, 2026.

TRAX Analyst Consensus

6 analysts cover TRAX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.50.

Common questions about TRAX

What are TRAX's key financials?
TRAX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRAX recently traded at $16.15. Market cap is $620.74M. P/E ratio is 0.00. Revenue is $0.
Is TRAX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRAX. It does not provide personalized investment advice.
TRAX

TRAX